MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic invariant natural killer T (iNKT) cell therapies for cancer, pulmonary, and immune-mediated diseases. The company advances a platform of off-the-shelf, native and engineered iNKT cell programs capable of targeting tumors and modulating immune responses, with demonstrated clinical evidence in oncology, acute respiratory distress syndrome (ARDS), and pulmonary fibrosis. Its manufacturing platform enables large-scale GMP-compliant production and clinical delivery of iNKT cell therapies without lymphodepletion or HLA matching. MiNK collaborates with leading academic and industry partners to advance novel cell-based immunotherapies.
Industries
N/A
MiNK Therapeutics
149 Fifth Avenue, Suite 500, New York, NY 10010, USA
Patents
T cell receptors that bind to mixed lineage leukemia (MLL)-specific phosphopeptides and methods of use thereof
2025-08-19 • US-12391741-B2
View DetailsT cell receptors that bind to mixed lineage leukemia (MLL)-specific phosphopeptides and methods of use thereof
2023-08-08 • US-11718658-B2
View DetailsT cell receptors that bind to NY-ESO-1 and methods of use thereof
2023-03-28 • US-11613764-B2
View Details
T cell receptors that bind to mixed lineage leukemia (MLL)-specific phosphopeptides and methods of use thereof
2025-08-19 • US-12391741-B2
View DetailsT cell receptors that bind to mixed lineage leukemia (MLL)-specific phosphopeptides and methods of use thereof
2023-08-08 • US-11718658-B2
View DetailsT cell receptors that bind to NY-ESO-1 and methods of use thereof
2023-03-28 • US-11613764-B2
View DetailsProducts
Off-the-shelf cell therapy product composed of allogeneic invariant natural killer T cells for anti-tumor and immunomodulatory activity in oncology and immune-mediated diseases.
Engineered cell therapy programs including chimeric antigen receptor-expressing iNKT (CAR-iNKT) cells and bispecific engager-armed iNKT cells for enhanced targeting of cancer.
Off-the-shelf cell therapy product composed of allogeneic invariant natural killer T cells for anti-tumor and immunomodulatory activity in oncology and immune-mediated diseases.
Engineered cell therapy programs including chimeric antigen receptor-expressing iNKT (CAR-iNKT) cells and bispecific engager-armed iNKT cells for enhanced targeting of cancer.
Expertise Areas
- Allogeneic cell therapy development
- Immuno-oncology
- Pulmonary disease therapeutics
- Clinical trial management
Key Technologies
- Allogeneic iNKT cell platform
- Chimeric antigen receptor engineering
- Bispecific engager technology
- Digital PCR-based cell tracking
Key People
President and CEO
Executive Director of Manufacturing
Director of Manufacturing
Head of Inflammatory and Pulmonary Diseases
Head of Translational Medicine
Senior Director, Portfolio Operations
President and CEO
Executive Director of Manufacturing
Director of Manufacturing
Head of Inflammatory and Pulmonary Diseases
Head of Translational Medicine
Senior Director, Portfolio Operations
News & Updates
Three scientific abstracts on allogeneic iNKT cell therapies accepted for presentation at a major immunotherapy meeting.
Company celebrated initial public offering by ringing the Nasdaq opening bell.
Coverage of trial evidence suggesting iNKT cell therapy improves survival in ARDS.
Presentation of clinical data showing durable responses and immune reactivation with allogeneic iNKT cell therapy in PD-1 refractory solid tumors at a major immunotherapy conference.
Announcement of the first patient dosed in a randomized Phase 2 clinical trial investigating iNKT cell therapy in ARDS.
New data of allogeneic iNKT cell therapy in idiopathic pulmonary fibrosis presented at Keystone Symposia.
Three scientific abstracts on allogeneic iNKT cell therapies accepted for presentation at a major immunotherapy meeting.
Company celebrated initial public offering by ringing the Nasdaq opening bell.
Coverage of trial evidence suggesting iNKT cell therapy improves survival in ARDS.
Presentation of clinical data showing durable responses and immune reactivation with allogeneic iNKT cell therapy in PD-1 refractory solid tumors at a major immunotherapy conference.
Announcement of the first patient dosed in a randomized Phase 2 clinical trial investigating iNKT cell therapy in ARDS.
New data of allogeneic iNKT cell therapy in idiopathic pulmonary fibrosis presented at Keystone Symposia.